Abstract：
UNASSIGNED: Psoriasis is a chronic inflammatory skin disease often associated with several comorbidities, such as psoriatic arthritis, inflammatory bowel disease, obesity, diabetes mellitus or cardiovascular diseases, infections, or cancer, among others. With the progressive aging of the population, a growing number of patients with psoriasis can be expected to present multiple comorbidities. Currently, there is a wide range of biological treatments available for moderate to severe psoriasis, including tumor necrosis alpha (TNF) inhibitors, IL12/23 inhibitor, IL17 inhibitors, and IL23 inhibitors.
UNASSIGNED: This review aims to describe the specific characteristics of these drugs in relation to psoriasis comorbidities, in order to facilitate decision-making in clinical practice.
UNASSIGNED: Some of the biological treatments can influence comorbidities, in some cases even improving them. Therefore, comorbidities are a key factor when deciding on one biological treatment over another. The development of new drugs is expanding the therapeutic arsenal for psoriasis. A high level of expertise in the field with a detailed knowledge of the characteristics of every drug is imperative to provide personalized medicine.
UNASSIGNED: This review aims to describe the specific characteristics of these drugs in relation to psoriasis comorbidities, in order to facilitate decision-making in clinical practice.
UNASSIGNED: Some of the biological treatments can influence comorbidities, in some cases even improving them. Therefore, comorbidities are a key factor when deciding on one biological treatment over another. The development of new drugs is expanding the therapeutic arsenal for psoriasis. A high level of expertise in the field with a detailed knowledge of the characteristics of every drug is imperative to provide personalized medicine.
摘要：
■银屑病是一种慢性炎症性皮肤病，常伴有多种合并症，比如银屑病关节炎，炎症性肠病，肥胖，糖尿病或心血管疾病，感染,或者癌症，在其他人中。随着人口的逐渐老龄化,预计越来越多的银屑病患者会出现多种合并症.目前,有广泛的生物治疗方法可用于中度至重度银屑病，包括肿瘤坏死α（TNF）抑制剂，IL12/23抑制剂，IL17抑制剂，和IL23抑制剂。
■这篇综述旨在描述这些药物与银屑病合并症有关的具体特征，以便于在临床实践中做出决策。
■一些生物治疗可以影响合并症，在某些情况下，甚至改进它们。因此,合并症是决定一种生物治疗而不是另一种生物治疗的关键因素。新药的开发正在扩大牛皮癣的治疗范围。必须在该领域拥有高水平的专业知识，并详细了解每种药物的特征，以提供个性化医疗。
■这篇综述旨在描述这些药物与银屑病合并症有关的具体特征，以便于在临床实践中做出决策。
■一些生物治疗可以影响合并症，在某些情况下，甚至改进它们。因此,合并症是决定一种生物治疗而不是另一种生物治疗的关键因素。新药的开发正在扩大牛皮癣的治疗范围。必须在该领域拥有高水平的专业知识，并详细了解每种药物的特征，以提供个性化医疗。
